- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01281254
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
To determine if AMG 386 plus pegylated liposomal doxorubicin (PLD) is superior to placebo plus PLD as measured by progression-free survival (PFS)
The hypothesis for this study is that AMG 386 plus PLD will prolong PFS compared to placebo plus PLD in women with recurrent partially platinum sensitive or resistant epithelial ovarian, primary peritoneal or fallopian tube cancer.
연구 개요
연구 유형
등록 (실제)
단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Grafton, Auckland, 뉴질랜드, 1023
- Research Site
-
Tauranga, 뉴질랜드, 3143
- Research Site
-
-
-
-
-
Tainan, 대만, 70403
- Research Site
-
Taipei, 대만, 10449
- Research Site
-
Taipei, 대만, 10041
- Research Site
-
-
-
-
-
Herlev, 덴마크, 2730
- Research Site
-
København, 덴마크, 2100
- Research Site
-
-
-
-
-
Berlin, 독일, 13353
- Research Site
-
Bonn, 독일, 53105
- Research Site
-
Düsseldorf, 독일, 40217
- Research Site
-
Erlangen, 독일, 91054
- Research Site
-
Essen, 독일, 45136
- Research Site
-
Frankfurt am Main, 독일, 60590
- Research Site
-
Freiburg, 독일, 79106
- Research Site
-
Hannover, 독일, 30177
- Research Site
-
Marburg, 독일, 35043
- Research Site
-
München, 독일, 81675
- Research Site
-
München, 독일, 81377
- Research Site
-
Rostock, 독일, 18059
- Research Site
-
Tübingen, 독일, 72076
- Research Site
-
-
-
-
California
-
Los Angeles, California, 미국, 90027
- Research Site
-
San Francisco, California, 미국, 94143
- Research Site
-
-
Connecticut
-
Norwalk, Connecticut, 미국, 06856
- Research Site
-
Stamford, Connecticut, 미국, 06902
- Research Site
-
-
Florida
-
Orlando, Florida, 미국, 32806
- Research Site
-
Tampa, Florida, 미국, 33612
- Research Site
-
-
Illinois
-
Evanston, Illinois, 미국, 60201
- Research Site
-
-
Minnesota
-
Saint Louis Park, Minnesota, 미국, 55426
- Research Site
-
-
New York
-
New York, New York, 미국, 10029
- Research Site
-
-
North Carolina
-
Asheville, North Carolina, 미국, 28806
- Research Site
-
Durham, North Carolina, 미국, 27710
- Research Site
-
Winston-Salem, North Carolina, 미국, 27103
- Research Site
-
-
North Dakota
-
Bismarck, North Dakota, 미국, 58501
- Research Site
-
-
Pennsylvania
-
Abington, Pennsylvania, 미국, 19001
- Research Site
-
-
South Dakota
-
Sioux Falls, South Dakota, 미국, 57104
- Research Site
-
-
Texas
-
Fort Sam Houston, Texas, 미국, 78234
- Research Site
-
San Antonio, Texas, 미국, 78229
- Research Site
-
-
Virginia
-
Annandale, Virginia, 미국, 22003
- Research Site
-
-
Wisconsin
-
Green Bay, Wisconsin, 미국, 54301
- Research Site
-
Milwaukee, Wisconsin, 미국, 53215
- Research Site
-
West Allis, Wisconsin, 미국, 53227
- Research Site
-
-
-
-
-
Charleroi, 벨기에, 6000
- Research Site
-
Edegem, 벨기에, 2650
- Research Site
-
Gent, 벨기에, 9000
- Research Site
-
Ieper, 벨기에, 8900
- Research Site
-
Leuven, 벨기에, 3000
- Research Site
-
Libramont, 벨기에, 6800
- Research Site
-
Liège, 벨기에, 4000
- Research Site
-
Namur, 벨기에, 5000
- Research Site
-
-
-
-
-
Aarau, 스위스, 5001
- Research Site
-
Chur, 스위스, 7000
- Research Site
-
Geneva 14, 스위스, 1211
- Research Site
-
Zurich, 스위스, 8091
- Research Site
-
-
-
-
-
Bratislava, 슬로바키아, 812 50
- Research Site
-
Bratislava, 슬로바키아, 831 01
- Research Site
-
Kosice, 슬로바키아, 041 91
- Research Site
-
Presov, 슬로바키아, 080 01
- Research Site
-
-
-
-
-
Singapore, 싱가포르, 169610
- Research Site
-
Singapore, 싱가포르, 229899
- Research Site
-
-
-
-
-
London, 영국, NW1 2PG
- Research Site
-
London, 영국, SW3 6JJ
- Research Site
-
London, 영국, SE1 9RT
- Research Site
-
Manchester, 영국, M20 4BX
- Research Site
-
Northwood, 영국, HA6 2RN
- Research Site
-
Nottingham, 영국, NG5 1PB
- Research Site
-
Poole, 영국, BH15 2JB
- Research Site
-
-
-
-
-
Graz, 오스트리아, 8036
- Research Site
-
Graz, 오스트리아, 8020
- Research Site
-
Innsbruck, 오스트리아, 6020
- Research Site
-
Linz, 오스트리아, 4010
- Research Site
-
Wien, 오스트리아, 1090
- Research Site
-
Wien, 오스트리아, 1160
- Research Site
-
-
-
-
-
Campobasso, 이탈리아, 86100
- Research Site
-
Genova, 이탈리아, 16128
- Research Site
-
Milano, 이탈리아, 20141
- Research Site
-
Milano, 이탈리아, 20133
- Research Site
-
Napoli, 이탈리아, 80131
- Research Site
-
Roma, 이탈리아, 00168
- Research Site
-
Roma, 이탈리아, 00128
- Research Site
-
Roma, 이탈리아, 00161
- Research Site
-
-
-
-
Ontario
-
London, Ontario, 캐나다, N6A 4L6
- Research Site
-
Toronto, Ontario, 캐나다, M5G 2M9
- Research Site
-
Toronto, Ontario, 캐나다, M4N 3M5
- Research Site
-
-
-
-
-
Bialystok, 폴란드, 15-027
- Research Site
-
Gdansk, 폴란드, 80-219
- Research Site
-
-
-
-
-
Amiens, 프랑스, 80000
- Research Site
-
Avignon cedex 9, 프랑스, 84918
- Research Site
-
Lyon cedex 8, 프랑스, 69373
- Research Site
-
Poitiers, 프랑스, 86021
- Research Site
-
Saint Cloud, 프랑스, 92210
- Research Site
-
-
-
-
-
Budapest, 헝가리, 1062
- Research Site
-
Budapest, 헝가리, 1032
- Research Site
-
Debrecen, 헝가리, 4032
- Research Site
-
Miskolc, 헝가리, 3526
- Research Site
-
Szeged, 헝가리, 6720
- Research Site
-
Zalaegerszeg - Pozva, 헝가리, 8900
- Research Site
-
-
-
-
New South Wales
-
New Lambton Heights, New South Wales, 호주, 2305
- Research Site
-
Wahroonga, New South Wales, 호주, 2076
- Research Site
-
-
Queensland
-
Auchenflower, Queensland, 호주, 4066
- Research Site
-
Greenslopes, Queensland, 호주, 4120
- Research Site
-
-
Victoria
-
East Bentleigh, Victoria, 호주, 3165
- Research Site
-
Footscray, Victoria, 호주, 3011
- Research Site
-
Malvern, Victoria, 호주, 3144
- Research Site
-
Parkville, Victoria, 호주, 3052
- Research Site
-
-
-
-
-
Hong Kong, 홍콩
- Research Site
-
New Territories, 홍콩
- Research Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Histologically or cytologically documented invasive epithelial ovarian, primary peritoneal, or fallopian tube cancer
- Radiographically documented disease progression either on or following the last dose of the prior regimen for epithelial ovarian, primary peritoneal, or fallopian tube cancer
- Subjects must have had one prior platinum-based chemotherapeutic regimen for management of primary disease containing carboplatin, cisplatin, or another organoplatinum compound.
- Female 18 years of age or older at the time the written informed consent is obtained
- Adequate organ and hematological function
Exclusion Criteria:
- Subjects who have received more than 3 previous regimens of anti cancer therapy for epithelial ovarian, primary peritoneal or fallopian tube cancer
- Subjects treated with prior pegylated liposomal doxorubicin (PLD) or any anthracycline-based or mitoxantrone-based chemotherapy
- Subjects with primary platinum-refractory disease
- Subjects with platinum-free interval (PFI) > 12 months from their last platinum based therapy
- History of central nervous system metastasis
- Major surgery within 28 days prior to randomization or still recovering from prior surgery
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
위약 비교기: Placebo plus PLD
Arm B: PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 placebo IV weekly (QW)
|
Pegylated Liposomal Doxorubicin (Doxil/Caelyx) is a preparation of doxorubicin in a liposome that contains surface-grafted segments of the hydrophilic polymer methoxypolyethylene glycol associated with prolonged pharmacokinetics of the free drug. PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 placebo IV weekly (QW) |
실험적: AMG386 plus PLD
Arm A: PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 15 mg/kg IV weekly (QW)
|
AMG 386 is a first in class investigational anti angiogenic drug that provides potent and selective inhibition of angiopoietins.
AMG 386 is designed to inhibit angiogenesis by sequestering Ang1 and Ang2, thereby preventing their interaction with the Tie2 receptor.
Pegylated Liposomal Doxorubicin (Doxil/Caelyx) is a preparation of doxorubicin in a liposome that contains surface-grafted segments of the hydrophilic polymer methoxypolyethylene glycol associated with prolonged pharmacokinetics of the free drug.
PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 15 mg/kg IV weekly (QW)
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
To determine if AMG 386 plus PLD is superior to placebo plus PLD as measured by progression-free survival, defined as the time from randomization to the earliest of the dates of first radiologic disease progression per RECIST 1.1 with modifications
기간: Radiological imaging will be performed 8 weeks ± 1 week, starting from date of randomization for the first 64 weeks, then every 16 weeks ± 1 week for the next 32 weeks, and then every 24 weeks ± 4 weeks thereafter.
|
Radiological imaging will be performed 8 weeks ± 1 week, starting from date of randomization for the first 64 weeks, then every 16 weeks ± 1 week for the next 32 weeks, and then every 24 weeks ± 4 weeks thereafter.
|
2차 결과 측정
결과 측정 |
기간 |
---|---|
• To determine if AMG 386 plus PLD is superior to placebo plus PLD as measured by overall survival
기간: weekly
|
weekly
|
공동 작업자 및 조사자
스폰서
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 20060517 (기타 식별자: Amgen. Inc.)
- 2009-017946-30 (EudraCT 번호)
- ENGOT-ov-6
- TRINOVA-2 (기타 식별자: Amgen, Inc)
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
난소 암에 대한 임상 시험
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen Breast Cancer...완전한
-
University of UtahNational Cancer Institute (NCI)모병피로 | 좌식 생활 | 전이성 전립선암 | IV기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVA기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVB기 전립선암 AJCC(American Joint Committee on Cancer) v8미국
-
Wolfson Medical Center빼는Ovarian Hyperstimulation Syndrome(OHSS)의 위험 감소를 위한 Coasting에 대한 GnRH 길항제의 증량 투여
-
Jonsson Comprehensive Cancer Center아직 모집하지 않음전립선암 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Rashmi Verma, MDNational Cancer Institute (NCI)모병거세저항성 전립선암 | 전이성 전립선 선암종 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center빼는전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer CenterMiraDX모집하지 않고 적극적으로전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center종료됨거세저항성 전립선암 | 전이성 전립선암 | IVA기 전립선암 AJCC v8 | IVB기 전립선암 AJCC v8 | IV기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Assiut University아직 모집하지 않음South Egypt Cancer Institute(SECI)에서 소아 악성종양 환자에 대한 KDIGO 기준을 사용하여 AKI의 누적 발병률을 확인하기 위해
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)모집하지 않고 적극적으로III기 전립선 선암종 AJCC v7 | II기 전립선 선암종 AJCC v7 | 1기 전립선 선암종 American Joint Committee on Cancer(AJCC) v7미국
Placebo plus PLD에 대한 임상 시험
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, Germany완전한
-
Istituto Clinico Humanitas Mater Domini아직 모집하지 않음
-
Morphotek완전한
-
Smith & Nephew Orthopaedics (Beijing) Limited완전한